TrialESMO open2024

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.

S A Hurvitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.